Loading
NASDAQHealthcareBiotechnology
Latest quote
$99.53
−$1.37 · -1.36%
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Previous close
$99.53
−$1.37 · -1.36%
Pre-market
$99.15
−$0.38 · -0.38%
Sep 9, 9:03 AM ET
Regular session · ET · Market data may be delayed.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Day range
Current $99.53
52-week range
Current $99.53
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
65
Undervalued
Sentiment
62
Bullish
Risk
32
Moderate Risk
Momentum
71
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Day range
Current $99.53
52-week range
Current $99.53
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 521.31M USD | 336.89M USD | 186.37M USD | 77.06M USD | 19.14M USD |
| Cost of goods sold | 100.58M USD | 81.64M USD | 47.04M USD | 12.37M USD | 1.9M USD |
| Gross profit | 420.73M USD | 255.25M USD | 139.34M USD | 64.69M USD | 17.24M USD |
| Research and development | 186.18M USD | 140.63M USD | 102.61M USD | 106.84M USD | 131.43M USD |
| Selling, general, and administrative | 257.03M USD | 202.22M USD | 145.88M USD | 89.07M USD | 59.22M USD |
| Operating expenses | 443.21M USD | 342.85M USD | 248.49M USD | 195.91M USD | 190.65M USD |
| Interest income | 12.73M USD | 13.79M USD | 13.74M USD | 3.86M USD | 366K USD |
| Interest expense | 14.39M USD | 14.31M USD | 15.11M USD | 15.98M USD | 17.59M USD |
| Depreciation and amortization | 24.24M USD | 23.63M USD | 10.83M USD | 3.24M USD | 975K USD |
| Operating income | −22.14M USD | −87.61M USD | −109.15M USD | −131.22M USD | −173.41M USD |
| Net income | −23.36M USD | −87.94M USD | −163.42M USD | −135.67M USD | −83.99M USD |
Company facts updated Sep 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$140.2
40.86% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI175.29M0.01%2.3T USD0.03%$377.6-0.56%
Vanguard Morningstar Small-Cap ETFVB126.27M0.07%183.4B USD0.03%$297.76-0.75%
iShares Russell 2000 ETFIWM122.31M0.15%80.51B USD0.19%$294.67-0.45%
State Street SPDR S&P Biotech ETFXBI114.08M0.99%11.43B USD0.35%$161.93-1.15%
Vanguard Morningstar Small-Cap Growth ETFVBK73.07M0.16%43.8B USD0.05%$347.9-0.44%
Vanguard Extended Market ETFVXF58.78M0.06%93.7B USD0.05%$241.35-0.54%
iShares Russell 2000 Growth ETFIWO44.41M0.30%14.7B USD0.24%$377.11-0.11%
iShares Biotechnology ETFIBB37.66M0.35%10.73B USD0.44%$207.33-2.17%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
